CLINICAL PAIN NEUROSCIENTIST TALKS ABOUT HOW THE BRAIN PROCESSES PAIN INFORMATION Trial: affects on pain and activity levels, by educating knee osteoarthritis participants in individualised exercise programs
With
Tasha Stanton,
Associate Professor of Clinical Pain Neuroscience
Group, Leader Persistent Pain Research Group (Lifelong Health)
SAHMRI (South Australian Health and Medical Research Institute) &
co-Director of IMPACT in Health, University of South Australia
SEGMENT
Filmed in Adelaide | March 2026
The Persistent Pain Research Group’s vision is to work hand-in-hand with consumers to undertake impactful research that helps better understand and treat persistent pain.
Their studies span discovery to implementation science to determine key contributors to the development and maintenance of persistent pain and to use this information to create novel brain-based interventions.
They hold expertise in developing new technologies, such as virtual and mediated reality, and translating these technologies to the clinical environment, using innovative co-design methods.
The Persistent Pain Research Group studies a variety of painful conditions, with specific focus on:
- Osteoarthritis
- Spinal pain (neck and back)
- Complex regional pain syndrome
- Phantom limb pain after amputation
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
Source: SAHMRI webpage Persistent Pain Research Group
You Might also like
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Outstanding Achievement
George FaithfullGeorge has been in the medical device industry in a variety of roles for over 35 years including Sales, Marketing, Business Development, General Management, R&D, Clinical, Regulatory and Government Affairs. He has worked for Stryker in Australia, USA and across Asia.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.